DK3458045T3 - Ebselen til anvendelse i behandling af menieres sygdom - Google Patents

Ebselen til anvendelse i behandling af menieres sygdom Download PDF

Info

Publication number
DK3458045T3
DK3458045T3 DK17800188.9T DK17800188T DK3458045T3 DK 3458045 T3 DK3458045 T3 DK 3458045T3 DK 17800188 T DK17800188 T DK 17800188T DK 3458045 T3 DK3458045 T3 DK 3458045T3
Authority
DK
Denmark
Prior art keywords
ebselen
meniere
disease
treatment
Prior art date
Application number
DK17800188.9T
Other languages
English (en)
Inventor
Jonathan Kil
Original Assignee
Sound Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Incorporated filed Critical Sound Pharmaceuticals Incorporated
Application granted granted Critical
Publication of DK3458045T3 publication Critical patent/DK3458045T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK17800188.9T 2016-05-18 2017-05-18 Ebselen til anvendelse i behandling af menieres sygdom DK3458045T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (1)

Publication Number Publication Date
DK3458045T3 true DK3458045T3 (da) 2024-11-04

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17800188.9T DK3458045T3 (da) 2016-05-18 2017-05-18 Ebselen til anvendelse i behandling af menieres sygdom

Country Status (19)

Country Link
US (1) US12427138B2 (da)
EP (2) EP4461360A3 (da)
JP (1) JP7100866B2 (da)
KR (1) KR102474830B1 (da)
CN (1) CN109475518A (da)
AU (1) AU2017267732B2 (da)
CA (1) CA3026007A1 (da)
DK (1) DK3458045T3 (da)
ES (1) ES2990157T3 (da)
FI (1) FI3458045T3 (da)
HR (1) HRP20241559T1 (da)
HU (1) HUE069280T2 (da)
LT (1) LT3458045T (da)
PL (1) PL3458045T3 (da)
PT (1) PT3458045T (da)
RS (1) RS66167B1 (da)
SI (1) SI3458045T1 (da)
SM (1) SMT202400469T1 (da)
WO (1) WO2017201318A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115135321B (zh) 2020-02-24 2023-12-05 上海科技大学 N-取代吡啶基苯并异硒唑酮化合物的应用
EP4452336A2 (en) * 2021-12-23 2024-10-30 University of Rochester Csf transport pathway for delivery of agents to inner ear
WO2023240094A1 (en) 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen
WO2023240092A1 (en) * 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Ebselen containing oral dosage forms

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
ATE119038T1 (de) 1988-12-09 1995-03-15 Allergan Inc Verwendung von 2-substituierten thiazolidin-4- carbonsäuren zur behandlung von katarakt.
KR20040078663A (ko) * 2002-01-04 2004-09-10 사운드 파마슈티칼스 인코퍼레이티드 난청의 치료 방법
WO2007044700A2 (en) * 2005-10-07 2007-04-19 Board Of Trustees Of Southern Illinois University Protectant combinations for reducing toxicities
AU2007277193B2 (en) * 2006-07-25 2013-06-13 Hough Ear Institute Methods for treating acute acoustic trauma
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
CA2732686C (en) 2008-12-22 2017-10-03 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CA2826602C (en) * 2011-02-04 2019-06-11 Hough Ear Institute Methods for treating brain injury
WO2013016727A1 (en) 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
CN102526734A (zh) * 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
US20150374779A1 (en) * 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
AU2015317877A1 (en) * 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
JP7033789B2 (ja) * 2016-06-29 2022-03-11 オトノミー,インク. トリグリセリド耳用製剤とその使用
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Also Published As

Publication number Publication date
HUE069280T2 (hu) 2025-02-28
EP3458045B1 (en) 2024-08-21
JP7100866B2 (ja) 2022-07-14
PL3458045T3 (pl) 2025-01-07
LT3458045T (lt) 2024-12-10
ES2990157T3 (es) 2024-11-29
WO2017201318A1 (en) 2017-11-23
US20200261417A1 (en) 2020-08-20
CN109475518A (zh) 2019-03-15
AU2017267732B2 (en) 2023-04-13
JP2019516727A (ja) 2019-06-20
US12427138B2 (en) 2025-09-30
SMT202400469T1 (it) 2025-01-14
EP4461360A2 (en) 2024-11-13
AU2017267732A1 (en) 2018-12-20
KR102474830B1 (ko) 2022-12-06
FI3458045T3 (fi) 2024-10-24
KR20190043499A (ko) 2019-04-26
EP3458045A1 (en) 2019-03-27
HRP20241559T1 (hr) 2025-02-14
EP4461360A3 (en) 2025-01-22
RS66167B1 (sr) 2024-12-31
PT3458045T (pt) 2024-10-28
CA3026007A1 (en) 2017-11-23
EP3458045A4 (en) 2020-09-16
SI3458045T1 (sl) 2025-03-31

Similar Documents

Publication Publication Date Title
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
MA45192A (fr) Traitement d'association
DK3364997T5 (da) Aspartoacylase genterapi til behandling af canavans sygdom
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
DK3562486T3 (da) Anvendelse af sublingual dexmedetomidin til behandling af agitation
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
IL251530B (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
FR3056393B1 (fr) Orthese d'extension de machoires
EP3487507A4 (en) VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
LT3463351T (lt) Parkinsono ligos gydymas
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3592355T3 (da) KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE063528T2 (hu) Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
DK3458045T3 (da) Ebselen til anvendelse i behandling af menieres sygdom
HUE061741T2 (hu) Maszk szemszárazság kezelésére
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra